Citations

Clear

6273 citation(s) found for "To, Andrew".

Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer
Moyer, Jacob A. , Durant, Adri , Nguyen, Mimi V., Mi, Lanyu , Zganjar, Andrew , Shah, Paras , Boorjian, Stephen A. , Tyson, Mark D. , Zganjar, Andrew J., Lyon, Timothy D.

Mayo Clinic

Journal of Urology | June 26, 2025 | Volume: 214 | Issue: 4 | Pages: 393-399

10.1097/ju.0000000000004658 | PMID 40569326 Get It

Genomic dimensions deconstruct the clinical heterogeneity of bipolar disorder
Veen, Tracey van der , Tesfaye, Markos , Yang, Jessica , Boltz, Toni , David, Friederike S. , Crinion, Shane , Koromina, Maria , Bigdeli, Tim B., Coombes, Brandon J., Panagiotaropoulou, Georgia, Parker, Nadine, Sung, Heejong , Bass, Nicholas, Coleman, Jonathan R. I., Guzman-Parra, José , Kálmán, János , McGrouther, Caroline C., Rangan, Aaditya V. , Scott, Katie , Vreeker, Annabel , Bauer, Michael , Brunkhorst-Kanaan, Nathalie, Byerley, William , Cervantes, Pablo , Chatzinakos, Chris , Claus, Isabelle , Cruceanu, Cristiana , Cuellar-Barboza, Alfredo, Dafnas, Konstantinos , Degenhardt, Franziska, Fanous, Ayman H. , Ferrier, I. Nicol , Forty, Liz , Frank, Josef , Freimer, Nelson B. , Hamshere, Marian L., Harder, Arvid , Hautzinger, Martin , Hellgren, Dennis, Hoffmann, Per, Jönsson, Lina , Kittel‐Schneider, Sarah , Knowles, James A. , Lavebratt, Catharina , Lawrence, Jacob , Leber, Markus , Lucae, Susanne , Lundberg, Martin , Maier, Wolfgang , Maihofer, Adam X. , Maratou, Eirini , McKay, James , Medeiros, Helena , Meyer‐Lindenberg, Andreas , Moutsatsou, Paraskevi , Mühleisen, Thomas W. , O’Connell, Kevin S. , Papiol, Sergi , Perry, Amy , Pisanu, Claudia , Potash, James B. , Rapaport, Mark Hyman , Regeer, Eline J. , Rice, John P. , Schulte, Eva C. , Senner, Fanny , Shilling, Paul D. , Sirignano, Lea , Slaney, Claire , Smeland, Olav B. , Sobell, Janet L. , Stein, Dan J. , Vawter, Marquis P. , Vedder, Helmut , Witt, Stephanie H. , Zandi, Peter P. , Investigators, Genomic Psychiatry Cohort (GPC), Psychiatry, HUNT All-In, Bengesser, Susanne , Berrettini, Wade H. , Blackwood, Douglas, Boehnke, Michael , Catts, Stanley V. , Craddock, Nicholas , Dikeos, Dimitris , Ferentinos, Panagiotis , Frye, Mark A. , Gawlik, Micha , Kahn, René S., Landén, Mikael , Lenger, Melanie , Loughland, Carmel , Melle, Ingrid , Myers, R , Müller‐Myhsok, Bertram , Neale, Benjamin M. , Øedegaard, Ketil J. , Paciga, Sara A. , Pato, Carlos N. , Pawlak, Joanna , Perlis, Roy H. , Reif, Andreas , Schalling, Martin , Scott, Laura J. , Scott, Rodney J., Stahl, Eli A. , Stordal, Eystein , Sullivan, Patrick F., Vaaler, Arne E. , Waldman, Irwin D. , Ophoff, Roel A. , Mullins, Niamh , Forstner, Andreas J. , van der Veen, Tracey , Yang, Jessica Mei Kay , Alda, Martin , Ophoff, Roel A , O'Connell, Kevin S , Mullins, Niamh , Forstner, Andreas J , Grigoroiu-Serbanescu, Maria , Edenberg, Howard J , McMahon, Francis , Andreassen, Ole A , Di Florio, Arianna , McQuillin, Andrew , Witt, Stephanie H , Meyer-Lindenberg, Andreas , Stein, Dan J , Papiol, Sergi , Cruceanu, Cristiana , Schulte, Eva , Kittel-Schneider, Sarah , Lavebratt, Catharina , Pisanu, Claudia , Reif, Andreas , Perlis, Roy H , Andlauer, Till F. M. , Bigdeli, Tim B. , Coombes, Brandon J. , Greenwood, Tiffany A. , Panagiotaropoulou, Georgia , Parker, Nadine , Bass, Nicholas, Coleman, Jonathan Ri , Mitchell, Brittany L. , Shadrin, Alexey A. , Smith, Daniel J. , Adorjan, Kristina , Albani, Diego , Alemany, Silvia , Alliey‐Rodriguez, Ney , Antoniou, Anastasia , Beins, Eva Carolina , Boks, Marco P. , Bosch, Rosa , Brumpton, Ben , Budde, Monika , Cabana‐Domínguez, Judit , Cairns, Murray J. , Carpiniello, Bernardo , Casas, Miguel , Clarke, Toni‐Kim , Cuéllar‐Barboza, Alfredo B. , Czerski, Piotr M. , Dale, Anders M. , Dalkner, Nina , DePaulo, J Raymond , Djurovic, Srdjan , Escott‐Price, Valentina , Fellendorf, Frederike T. , Frei, Oleksandr , Garnham, Julie , Gizer, Ian R. , Gordon, Scott D. , Gordon‐Smith, Katherine , Hahn, Tim , Hamshere, Marian L. , Heilbronner, Urs , Herms, Stefan , Hickie, Ian Bernard , Hoffmann, Per , Holmans, Peter , Jamain, Stéphane , Kennedy, James L. , Koch, Elise , Kogevinas, Manolis , Kranz, Thorsten M. , Kushner, Steven A. , Lind, Penelope A. , Lundberg, Martin, MacIntyre, Donald J. , Malaspina, Dolores , Manchia, Mirko , Martinsson, Lina , McInnis, Melvin G. , Millischer, Vincent , Morris, Derek W. , Olsen, Catherine M. , Pardiñas, Antonio F. , Pfennig, Andrea , Quested, Digby J. , Rivera, Margarita , Sindermann, Lisa , Siskind, Dan , Artigas, María Soler , Stein, Frederike , Świątkowska, Beata , Thorp, Jackson G. , Toma, Claudio , Tondo, Leonardo , Tooney, Paul A. , Walters, James , Young, Allan H. , Zillich, Lea , Adolfsson, Rolf , Alfredsson, Lars , Backlund, Lena , Baune, Bernhard , Bellivier, Frank , Biernacka, Joanna M. , Blackwood, Douglas , Breen, Gerome , Carr, Vaughan J , Cichon, Sven , Corvin, Aiden , Dannlowski, Udo , Esko, Tõnu , Étain, Bruno , Fullerton, Janice M. , Gershon, Elliot S. , Goes, Fernando , Green, Melissa J. , Hauser, Joanna , Henskens, Frans A , Hjerling‐Leffler, Jens , Jones, Ian Richard , Jones, Lisa Anne , Kahn, René S. , Kelsoe, John R , Kircher, Tilo , Kirov, George , Kobayashi, Nene, Leboyer, Marion , Li, Qingqin S. , Lissowska, Jolanta , Loughland, Carmel M. , Luykx, Jurjen J. , Martin, Nicholas G. , Mathews, Carol A. , Mayoral, Fermín , McElroy, Susan L. , McIntosh, Andrew M. , Medland, Sarah E. , Mitchell, Philip B , Morken, Gunnar , Möser, Chiara, Nievergelt, Caroline M , Nurnberger, John I , Nöthen, Markus M. , O‘Donovan, Michael , Olsson, Tomas , Owen, Michael J. , Pantelis, Christos , Pato, Michele T. , Patrinos, George P. , Ramos‐Quiroga, Josep Antoni , Reininghaus, Eva , Ribasés, Marta , Rietschel, Marcella , Ripke, Stephan , Rouleau, Guy Armand , Schall, Ulrich , Schofield, Peter R. , Schulze, Thomas , Scott, Rodney J. , Serretti, Alessandro , Smoller, Jordan W. , Squassina, Alessio , Streit, Fabian , Turecki, Gustavo , Vieta, Eduard , Vincent, John B. , Weickert, Cynthia Shannon , Weickert, Thomas Wesley , Whiteman, David C. , Alda, Martin , Grigoroiu‐Serbânescu, Maria , McMahon, Francis J. , Andreassen, Ole A. , McQuillin, Andrew

Mayo Clinic

No container title available | June 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.23.25330155 | PMID 40666370 Get It

ABSTRACT Bipolar disorder’s (BD) clinical heterogeneity has an unresolved genetic basis. We meta-analyzed genome-wide association studies (GWAS) of 16 BD subphenotypes in 226,032 individuals from 57 cohorts (38,022 cases); 10 advanced to multivariate and multi-trait analyses. Four factors (compulsive, psychotic, dysregulated, internalizing) explained 82.8% of shared genetic variance. BD1 and BD2 loaded on distinct factors despite a high genetic correlation; 87.0% of common-factor loci were significant in neither subtype. Unipolar mania aligned with psychosis over internalizing, and was distinguishable from BD1, and rapid cycling showed heritable cross-domain liability. We identified 356 risk loci, 158 novel, including the first univariate-GWAS associations for psychosis, unipolar mania, rapid cycling and schizoaffective disorder—and 249 credible genes (89 high-confidence), 12 with approved-drug or clinical-phase annotations. Cell-type association showed a midbrain dopaminergic–GABAergic gradient along the psychotic factor. BD’s genetic architecture appears hierarchical—a general liability resolving into dimensions of course and comorbidity beyond diagnostic subtypes.
A Novel Testing Battery for Preserved Autonomic Regulation Following Spinal Cord Injury and New Translationally Focused Data Representation
Burns, Kathryn , Veith, Daniel D. , Solinsky, Ryan , Hamner, Jason W. , Singer, Wolfgang , Taylor, J. Andrew

Mayo Clinic

Topics in Spinal Cord Injury Rehabilitation | June 24, 2025 | Volume: 31 | Issue: 2 | Pages: 50-61

10.46292/sci24-00071 | PMID 40585014 Get It

Background: Autonomic dysfunction is common after spinal cord injury (SCI). There are currently limited tools to comprehensively characterize its deficits. While individual established autonomic tests have a long history and sound scientific background, translating these autonomic testing results to inform clinical understanding is a major barrier. Objectives: To assess a strategic battery of autonomic tests to characterize and act as a biomarker of autonomic regulation for individuals with SCI and to develop a novel graphical representation of these data to facilitate understanding of autonomic dysfunction after SCI. Methods: We outline a battery of six laboratory autonomic tests that were curated to collectively describe the ability of individuals with SCI to inhibit and recruit sympathetic activity through the injured spinal cord. Heart rate/blood pressure variability, bolus phenylephrine, hand and foot cold pressor, Valsalva maneuver, and bladder pressor are herein described. Incorporating normative control data for 30 uninjured individuals completing this testing battery, we further demonstrate the utility of a composite biomarker, comparing these control results to 11 individuals with SCI. Results: Results demonstrate strong normality of data with testing psychometrics, suggesting stable reproducibility with repeat testing. Even in this preliminary sample of individuals with SCI, clear differences begin to emerge compared to uninjured norms. This illustrates the ability of this collective testing battery to characterize autonomic regulation after SCI. To aid in clinical translation, we further present a graphical representation, an autonomic phenotype , which serves as a snapshot of how normal or abnormal sympathetic inhibition and recruitment of activation may be after SCI. Conclusion: Utilizing these autonomic phenotypes, three example cases of individuals with SCI highlight evidence of varied degrees of autonomically complete SCI. Together, this represents a key advancement in our understanding of autonomic function after SCI.
Health information technology interventions reduce avoidable readmissions in cirrhosis: The HEROIC randomized controlled trial
Shaw, Jawaid , Acharya, Chathur , Olofson, Amy , Irwin, Kelsey, Kohlekar, Sunil, Kamath, Patrick S. , Bajaj, Jasmohan S. , Bajaj, Jasmohan S , Fagan, Andrew, Irwin, Kelsey, Thacker, Leroy R.

Mayo Clinic

Hepatology | June 24, 2025 | Volume: 83 | Issue: 5 | Pages: 1204-1214

10.1097/hep.0000000000001424 | PMID 40552924 Get It

Background and Aims: Reducing avoidable readmissions in cirrhosis is challenging. Enhanced engagement using health information technology (HIT) interventions and caregivers lowered readmissions in an open-label study of the Patient Buddy App (PBA). Aim : Multicenter trial of PBA versus standard of care (SOC) to reduce avoidable readmissions. Approach and Results: An open-label, randomized clinical trial was performed at 3 sites to study the effect of PBA (HIT) versus SOC in cirrhosis inpatients with adult caregivers (dyads). Initial randomization was 1:1:1 between SOC, HIT only, and HIT+ visits. However, due to COVID-19, an unplanned study redesign required a combined HIT versus SOC. Primary outcome : Avoidable readmissions (decided by a blinded monitoring board). Secondary outcomes were all-cause readmission and stakeholder input. PBA focused on medication adherence, cognitive testing, and symptoms, and was remotely monitored by study staff. In all, 464 subjects (232 dyads) were enrolled [Virginia Commonwealth University (VCU): 120, Mayo: 40, Department of Veterans Affairs (VA): 72; 116 dyads/group]. Avoidable readmissions were significantly higher in SOC versus HIT (19.8% vs. 10.3%, p =0.04) with OR of 2.14 (95% CI 1.01–4.54) and remained significant even after removing pre-COVID HIT+ visits patients (19.8% vs. 9.3%, p =0.040) with OR of 2.41 (95% CI 1.02–5.69). All-cause readmissions were higher in SOC versus HIT (48% vs. 30%, p =0.005). App evaluation/engagemen t : 1660 alerts were sent; mostly related to HE. Most dyads were satisfied with the app. Conclusions: In a multicenter randomized clinical trial of 464 cirrhosis inpatients and their CGs across several practice settings, the PBA was associated with lower avoidable readmissions at 30 days post-discharge compared to SOC.
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment
DeFronzo, Ralph A. , Fonseca, Vivian , Aroda, Vanita R. , Auchus, Richard J. , Busch, Robert S. , Buse, John B. , Christofides, Elena A. , Eilerman, Bradley , Findling, James W. , Handelsman, Yehuda , Miller, Harold J., Ownby, Jonathan G., Parker, John C. , Philis‐Tsimikas, Athena , Rosenstock, Julio , Shanik, Michael H., Sloan, Lance Alan , Shambharkar, Samir, Tudor, Iulia Cristina , Schlafly, Tina K. , Einhorn, Daniel , Investigators*, CATALYST, Kruszon, Lauren, Fruiterman, Abbey, Heidarpour, Narges, Ownby, Jonathan G., Stephens, Nashia, Gyurko, Rita, Rao, Pratibha, Paulus, Kelly, Kipnes, Mark, Ryan, Terri, Iannuzzi, Lisa, Centeno, Gloria, Castro-Revoredo, Iris, Eskeland, Andrew, Swerdloff, Ronald S., Ruiz, Elizabeth, Park, Jean, Hurtado, Maria, Ghazi, Adline , Hamm, M., Ducote, Rosina, Blonde, Lawrence , Williams, Shannon, Wyne, Kathleen , Aldrich, Lindsey, Ahmann, Andrew , Branigan, Deborah , Nakhle, Samer, Sandry, Sasha, Rosal, Rosario, Hardy, Cashmere, Sloan, Lance , Sloan, Kátia Portero , Lerman, Sam, Simmons, Mary, Varela, Tamara Blanco, Gassaway, Franziska, Puckett, Curtiss, Atkinson, Karen, Zimmerman, Michael, Jacobsen, Colleen, Wenker, Matthew, Schultz, Austin, Lender, Dan, Camacho, Allison, Leibowitz, Mark D., Sánchez, Rosario, Delgado, John , Jaasko, Kari, Hsia, Stanley H. , Rodríguez, Cecilia, Guzman, David , Garibay, Lourdes, Chang, Margaret, Nixon, Tatyana, Buse, John B , Christofides, Elena A , Eilerman, Bradley , Handelsman, Yehuda , Kahn, Steven , Rosenstock, Julio , Umpierrez, Guillermo E. , Schlafly, Tina K , Philis-Tsimikas, Athena , DeFronzo, Ralph A , Fonseca, Vivian , Bailey, Timothy S. , Bancos, Irina , Kahn, Steven E. , Pratley, Richard E. , Shambharkar, Samir, Investigators*, CATALYST, Ownby, Jonathan G., Centeno, Gloria, Castro-Revoredo, Iris, Ruiz, Elizabeth, Aldrich, Lindsey, Botte, Jennifer, Hardy, Cashmere, Martin, Maria Jesus , Lovre, Dragana , Simmons, Mary, Pop‐Busui, Rodica , Zimmerman, Michael, Wenker, Matthew, Schultz, Austin, Chang, Margaret, Nixon, Tatyana

Mayo Clinic

Diabetes Care | June 23, 2025 | Volume: 48 | Issue: 12 | Pages: 2036-2044

10.2337/dc25-1055 | PMID 40550011 Get It

OBJECTIVE In many individuals, type 2 diabetes (T2D) remains poorly controlled despite taking multiple glucose-lowering therapies. Several studies have demonstrated that endogenous hypercortisolism is prevalent among these individuals. We tested whether cortisol-directed therapy improves their glycemic control. RESEARCH DESIGN AND METHODS In this prospective, multicenter, double-blind study, 136 individuals with T2D (hemoglobin A1c [HbA1c] 7.5%–11.5% [58–102 mmol/mol] on multiple medications) and hypercortisolism (by dexamethasone suppression test) were randomized 2:1 to the glucocorticoid receptor antagonist mifepristone (300–900 mg once daily; n = 91) or placebo (n = 45) for 24 weeks, with stratification by presence/absence of an adrenal imaging abnormality. The primary end point was the change in HbA1c. Secondary end points included changes in glucose-lowering medications, weight, and waist circumference and safety. RESULTS Mean baseline HbA1c in the study cohort was 8.55% (69.9 mmol/mol). At 24 weeks, the least squares mean (LSM) difference from placebo in HbA1c was −1.32% (95% CI −1.81 to −0.83; P < 0.001). Participants receiving mifepristone experienced reductions in body weight and waist circumference (placebo-adjusted LSM differences of −5.12 kg [95% CI −8.20 to −2.03] and −5.1 cm [−8.23 to −1.99], respectively). Of participants on mifepristone, 46% discontinued therapy, compared with 18% on placebo. Adverse events with mifepristone (>10% of participants) included hypokalemia, fatigue, nausea, vomiting, headache, peripheral edema, diarrhea, and dizziness, consistent with mifepristone’s known tolerability profile. Increases in blood pressure also occurred. CONCLUSIONS In individuals with inadequately controlled T2D and hypercortisolism, cortisol-directed medical therapy with mifepristone reduced HbA1c, with a manageable tolerability profile.
P57 Efficacy of risankizumab versus ustekinumab by disease duration in moderate-to-severe crohn’s disease: phase 3 SEQUENCE post-hoc analysis
Peyrin-Biroulet, Laurent, Ben‐Horin, Shomron, Ha, Christina , Aponte, Fernando, Kligys, Kristina, Zambrano, Javier , Anschutz, Toni , Garrison, Andrew, Peyrin‐Biroulet, Laurent , Ben‐Horin, Shomron , Siegmund, Britta , Colombel, Jean‐Frédéric

Mayo Clinic

Posters | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A123.2-A124

10.1136/gutjnl-2025-bsg.193 Get It

Recent-onset atrial fibrillation: challenges and opportunities
Svennberg, Emma , Andrade, Jason G. , Anselmino, Matteo , Biton, Yitschak , Brandes, Axel , Buckley, Claire , Espuny, Josep Lluis Clua , Doehner, Wolfram , Domínguez, Helena , Fauchier, Laurent , Glotzer, Taya V. , Hendriks, Jeroen , Hills, Mellanie True , Hindricks, Gerhard , Joung, Boyoung , Levin, Lars‐Åke , Liu, Shaowen , Lobban, Trudie , Macfarlane, Peter W. , Mairesse, Georges H. , Marcus, Gregory M. , Orchard, J. , Reiffel, James A. , Siontis, Konstantinos C. , Stavrakis, Stavros , Svendsen, Jesper Hastrup , Teh, A. , Tieleman, Robert G , Camm, A. John , Freedman, Ben , Andrade, Jason G , Anselmino, Matteo , Biton, Yitschak , Boriani, Giuseppe , Brandes, Axel , Buckley, Claire , Cameron, Alan C , Lluis Clua Espuny, Josep , Crijns, Harry J G M , Diederichsen, Søren Z , Doehner, Wolfram , Dominguez, Helena , Duncker, David , Fauchier, Laurent , Glotzer, Taya , Guo, Yutao , Haeusler, Karl G , Haim, Moti , Healey, Jeffrey S , Hendriks, Jeroen M , True Hills, Mellanie , Hindricks, Gerhard , Hobbs, F D Richard , Johnson, Linda S B , Joung, Boyoung , Kamel, Hooman , Kirchhof, Paulus , Lane, Deirdre A , Levin, Lars-Åke , Lip, Gregory Y H , Liu, Shaowen , Lobban, Trudie , Macfarlane, Peter W , Mairesse, Georges , Marcus, Gregory M , Noseworthy, Peter A , Ntaios, George , Orchard, Jessica J , Passman, Rod , Reidpath, Daniel D , Reiffel, James A , Ribeiro, Antonio Luiz , Rivard, Lena , Sanders, Prashanthan , Sandhu, Roopinder K , Schnabel, Renate B , Siontis, Konstantinos C , Sposato, Luciano A , Stavrakis, Stavros , Steinhubl, Steven , Svendsen, Jesper Hastrup , Teh, Andrew W , Themistoclakis, Sakis , Tieleman, Robert G , Camm, Alan John , Freedman, Ben , Boriani, Giuseppe , Cameron, Alan C. , Crijns, Harry J.G.M. , Diederichsen, Søren Zöga , Duncker, David , Haim, Moti , Healey, Jeff S. , Hobbs, Richard , Johnson, Linda S.B. , Kamel, Hooman , Kirchhof, Paulus , Lane, Deirdre A. , Noseworthy, Peter A. , Passman, Rod , Rivard, Léna , Sanders, Prashanthan , Schnabel, Renate B. , Sposato, Luciano A. , Tieleman, RG

Mayo Clinic

European Heart Journal | June 23, 2025 | Volume: 47 | Issue: 2 | Pages: 170-187

10.1093/eurheartj/ehaf478 | PMID 40873195 Get It

Abstract Atrial fibrillation (AF) is increasingly diagnosed early, close to its first occurrence due to: (i) increased public awareness with self-screening; (ii) health care initiatives including population screening and opportunistic case finding; and (iii) increased use and surveillance of implantable cardiac devices. At its onset, AF is often low burden, and cardiovascular co-morbidities may be absent or at an early stage. Thus, the management of recent-onset AF has become an issue of growing importance. Professional guidelines have traditionally focused on anticoagulant thromboprophylaxis, generally recommending a cautious approach to rhythm control, and priority has been given to rate control to alleviate symptoms. In recent guidelines, the importance of managing lifestyle and co-morbidities has increased. The AF-SCREEN collaboration proposes that a vigorous approach to active management of recent-onset AF may be warranted. This includes addressing co-morbidities and promoting healthy lifestyles to prevent the emergence or progression of AF and associated cardiovascular disease, as well as the initiation of active rhythm control ± anticoagulation to prevent AF-related morbidity and mortality, including stroke and heart failure (HF). Intuitively, intervention early after AF onset would be beneficial since lifestyle and co-morbidity management, plus rhythm control and anticoagulation, are important contributors to improved outcomes in patients with established AF, but robust evidence is lacking for recent-onset AF. There is a delicate balance between achieving favourable outcomes such as preventing strokes, HF and AF progression vs the complications and potential adverse effects of interventions. Given the serious long-term consequences, innovative approaches are necessary to determine the value and risks of initiating active therapy very early in the course of AF. More data are needed to guide the best management of recent-onset AF, bearing AF burden in mind. Long-term studies using large national databases linked to electronic medical records and rhythm monitoring devices offer excellent opportunities. Shorter-term studies focusing on reducing AF burden to slow AF progression and studies focusing on outcomes such as HF could be used in both randomized clinical trials and observational cohort studies.
Radiographic and pathologic response of myxoid liposarcoma treated with preoperative radiotherapy
Gao, Robert W. , Thangaiah, Judith Jebastin, Wenger, Doris E. , Harmsen, William S. , Folpe, Andrew L. , Haddock, Michael G. , Petersen, Ivy A. , Jebastin, Judith As, Ahmed, Safia K.

Mayo Clinic

Radiology and Oncology | June 22, 2025 | Volume: 59 | Issue: 2 | Pages: 176-182

10.2478/raon-2025-0032 | PMID 40544504 Get It

Abstract Background We retrospectively assessed volumetric response of myxoid liposarcoma (MLPS) with preoperative radiotherapy (RT) and sought to identify disease and treatment characteristics associated with response. Patients and methods We identified all patients with a histologic diagnosis of MLPS who received preoperative RT from 2013 to 2021 at our institution. We used cone beam computed tomography (CBCT) to assess changes in tumor volume and greatest dimension during treatment. Tumors were contoured on CBCT images prior to treatment and at the end of each week of RT. Percentage change in tumor volume and greatest dimension were calculated based on pre-treatment and final week contours. Patients with tumors incompletely visualized on CBCT were excluded from volume analysis but included on greatest dimension analysis. Magnetic resonance imaging (MRI) was used to evaluate pre- and post-RT radiographic features. Surgical pathology was reviewed to record pathologic characteristics. Results Twenty patients met inclusion criteria. Most tumors (18/20) were low grade. The most frequent dose/fractionation scheme was 50 Gy in 25 fractions (16/20), with 3 patients receiving 36 Gy in 18 fractions. Median pre-RT volume and greatest dimension were 120 cc (interquartile range [IQR]: 56–399) and 11.2 cm (IQR: 8.4–14.1), respectively. Median percentage change in volume and greatest dimension were -37% (IQR: -57 to -29) and -10% (IQR: -20 to -7). All evaluable tumors decreased in volume during RT. Between pre- and post-RT MRI, most patients had a decrease in intratumoral (16/20) and peritumoral edema (11/20). Sixteen patients exhibited extensive pathologic response. There were no significant associations between radiographic and pathologic features and volumetric change. Local failure at 3 years was 9% (95% confidence interval: 1–59). Conclusions We report significant decreases in MLPS tumor size during preoperative RT. There may be a role for adaptive RT planning to reduce target volumes and minimize RT-associated morbidity.
Transitions Within and Use of Outpatient Primary and Oncology Care in Survivors of Adolescent and Young Adult-Onset Cancers
Haupt, Eric C. , Chawla, Neetu , Osuji, Thearis A. , Shen, Ernest , Casperson, Mallory, Kirchhoff, Anne C. , Zebrack, Brad , Laurent, Cecile A. , Keegan, Theresa H.M. , Abrahão, Renata , Ruddy, Kathryn J. , Nichols, Hazel B. , Wernli, Karen J. , Hahn, Erin E , Haupt, Eric C , Chawla, Neetu , Kirchhoff, Anne C , Zebrack, Bradley J , Laurent, Cecile A , Keegan, Theresa H M , Abrahão, Renata , Ruddy, Kathryn J , Chubak, Jessica , Nichols, Hazel B , Wernli, Karen J , Smitherman, Andrew B. , Chubak, Jessica

Mayo Clinic

JCO Oncology Practice | June 20, 2025 | Volume: 22 | Issue: 5 | Pages: 780-792

10.1200/op-24-00886 | PMID 40540706 Get It

PURPOSE Survivors of adolescent and young adult (AYA)-onset cancers require comprehensive cancer surveillance care. Guidelines recommend 1-4 clinician visits annually for 5 years depending on stage and disease. The goal of this study was to identify factors associated with patterns of post-treatment primary and oncology care in a large cohort of survivors of AYA-onset cancers diagnosed within an integrated health care system. METHODS Patients diagnosed with cancer between 2006 and 2020 age 15-39 years were included. Surveillance visits were identified from electronic medical records 2-5 years after diagnosis. Multivariable logistic regression was used to assess associations with zero oncology specialty visits. RESULTS Of 7,925 survivors, 46% were Hispanic, 6% non-Hispanic Black, 11% non-Hispanic Asian, 35% non-Hispanic White, and 65% female. One-quarter had no oncology specialty visits in the first surveillance year rising to 38% in year 5; 31% had 3+ visits in the first year, declining to 13% in year 5. Over the surveillance period, 17% did not have any oncology specialty visits and 6% had no primary care or oncology visits. Those who were male (odds ratio [OR], 1.21 [95% CI, 1.02 to 1.45]), 20-24 years at diagnosis (OR, 1.58, 95% CI, 1.27 to 1.9; v 35 to 39), or non-Hispanic Black (OR, 1.38, 95% CI, 1.05 to 1.82; v non-Hispanic White) or had high-deductible commercial or Medicaid insurance (OR, 1.35, 95% CI, 1.15 to 1.59; OR, 1.42, 95% CI, 1.11 to 1.82, respectively; v no or low deductible commercial) were more likely to be in the 0-visit group for oncology specialty care. CONCLUSION Although the majority of this cohort received either primary or oncology specialty care, our study identifies those who may need tailored outreach for follow-up care. Continued research into development and testing of interventions to improve uptake of appropriate health care for survivors of AYA-onset cancers is critical.